CPX-351 (Liposomal Cytarabine and Daunorubicin)
Treatment for Acute Myeloid Leukemia
Typical Dosage: Cytarabine 100 mg/m² and Daunorubicin 44 mg/m² IV on days 1, 3, 5
Effectiveness
78%
Safety Score
25%
Clinical Trials
43
Participants
1K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Cytarabine 100 mg/m² and Daunorubicin 44 mg/m² IV on days 1, 3, 5
Time to Effect
3-4 weeks
Treatment Duration
Induction (days 1,3,5) then 2 consolidation cycles (total 3-5 months)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$250,000
Monitoring:$150,000
Side Effect Mgmt:$75,000
Total Annual:$475,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$233,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$995,807
Cost per Remission
$995,807
Comparison vs Cytarabine + Daunorubicin ("7+3")
Cost Difference
+$200,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
CPX-351 (Liposomal Cytarabine and Daunorubicin) Outcomes
for Acute Myeloid Leukemia
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+47.7%
Remission Rate
+47.7%
Common Side Effects
Febrile neutropenia
+75%
Hemorrhage
+60%
Nausea
+50%
Diarrhea
+50%
Fatigue
+40%
Edema
+35%
Myelosuppression
+100%
Sources:
Active Clinical Trials
4 active trials recruiting for CPX-351 (Liposomal Cytarabine and Daunorubicin) in Acute Myeloid Leukemia
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
NCT07008638RECRUITINGPHASE1, PHASE2
32 participants
INTERVENTIONAL
Minneapolis, United States
Started: Jul 7, 2025
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
NCT04128748RECRUITINGPHASE1, PHASE2
52 participants
INTERVENTIONAL
Houston, United States
Started: May 27, 2020
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT04493164RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Houston, United States
Started: Dec 30, 2020
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
NCT04269213ACTIVE NOT RECRUITINGPHASE2
21 participants
INTERVENTIONAL
Omaha, United States +3 more
Started: Jul 29, 2021
Completed Clinical Trials
9 completed trials for CPX-351 (Liposomal Cytarabine and Daunorubicin) in Acute Myeloid Leukemia
CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02019069COMPLETEDPHASE2
11 participants
INTERVENTIONAL
Stanford, United States
Started: Feb 3, 2014
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
NCT00788892COMPLETEDPHASE2
126 participants
INTERVENTIONAL
Tucson, United States +27 more
Started: Oct 1, 2008
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT01804101COMPLETEDNA
48 participants
INTERVENTIONAL
Palo Alto, United States +1 more
Started: May 7, 2013
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
NCT02286726COMPLETEDPHASE2
56 participants
INTERVENTIONAL
Houston, United States
Started: May 4, 2015
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
NCT04915612COMPLETEDPHASE1
1 participants
INTERVENTIONAL
Houston, United States
Started: May 21, 2021
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
NCT03555955COMPLETEDPHASE1
21 participants
INTERVENTIONAL
Washington D.C., United States +12 more
Started: Nov 20, 2018
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
NCT03844997COMPLETEDPHASE1, PHASE2
35 participants
INTERVENTIONAL
Cleveland, United States
Started: Jun 6, 2019
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
NCT01696084COMPLETEDPHASE3
309 participants
INTERVENTIONAL
Birmingham, United States +42 more
Started: Dec 13, 2012
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
NCT00875693COMPLETEDPHASE1
47 participants
INTERVENTIONAL
New York, United States
Started: Jun 2, 2009
Showing 20 of 43 total trials